熱門資訊> 正文

Neurogene GAAP每股收益为-1.19美元

2024-11-19 14:55

Neurogene press release (NASDAQ:NGNE): Q3 GAAP EPS of -$1.19 in-line.
Cash, cash equivalents and investments as of September 30, 2024 were $139.0 million.
The company continues to expect current cash, cash equivalents and marketable securities, together with an estimated $189.5 million in net proceeds from the private placement, to fund operations into the second half of 2027.

More on Neoleukin Therapeutics

Neurogene: Interesting CNS Disease Company, Data Coming Soon
Neurogene stock plunges 36% on NGN-401 study update
Neurogene plummets 35% on gene therapy trial data for Rett syndrome
Historical earnings data for Neoleukin Therapeutics
Financial information for Neoleukin Therapeutics

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。